Log in to search using one of your social media accounts:

 

FDA approves novel preventive treatment for migraine
The U.S. Food and Drug Administration today approved Aimovig (erenumab-aooe) for the preventive treatment of migraine in adults. The treatment is given by once-monthly self-injections. Aimovig is the first FDA-approved preventive migraine treatment in a new class of drugs that work by blocking the activity of calcitonin gene-related peptide, a molecule that is involved in migraine attacks. (Source: World Pharma News)
Source: World Pharma News - May 18, 2018 Category: Pharmaceuticals Tags: Featured FDA Regulatory Affairs Source Type: news

Doctors in US and Canada launch sweeping pharmaceutical reform proposal
The skyrocketing cost of prescription drugs is one of the biggest concerns for American voters. However, in his proposal last Friday, President Donald Trump failed to offer any new policies that would expand access, reduce costs, or increase the safety and efficacy of prescriptions. Today, a group of 21 prominent physicians published a comprehensive proposal to ensure universal access to safe, innovative, and affordable medications. (Source: World Pharma News)
Source: World Pharma News - May 17, 2018 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

SMi presents the launch of Cell & Gene Therapy 2018
10 - 11 October, London, UK. SMi introduces their inaugural event on Cell & Gene Therapy which takes place between the 10th and 11th October 2018, with an interactive pre-conference workshop on the 9th October. Cell and gene therapeutics have revolutionised modern medicine and mark a new generation in biomedical and agricultural sciences. The latest developments in cell and gene therapies and specifically in gene editing, technologies present unlimited research opportunities ranging from novel therapeutic tools to a potential revolution in the field of drug discovery. (Source: World Pharma News)
Source: World Pharma News - May 17, 2018 Category: Pharmaceuticals Tags: Featured Events Source Type: news

Stroke prevention drug combo shows promise
If you've had a minor stroke or a transient ischemic stroke (TIA), taking the clot-preventing drug clopidogrel along with aspirin may lower your risk of having a major stroke within the next 90 days, according to new research published in The New England Journal of Medicine. (Source: World Pharma News)
Source: World Pharma News - May 16, 2018 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Novo Nordisk increases commitment to stem cell-based therapies
Novo Nordisk today announced an increased commitment to stem cell-based therapies and an expansion of the focus on type 1 diabetes into other serious chronic diseases. This has been made possible through an exclusive collaboration with the University of California San Francisco (UCSF) in which a first milestone in the development of human embryonic stem cell lines has been reached. (Source: World Pharma News)
Source: World Pharma News - May 16, 2018 Category: Pharmaceuticals Tags: Featured Novo Nordisk Business and Industry Source Type: news

FDA approves first epoetin alfa biosimilar for the treatment of anemia
The U.S. Food and Drug Administration today approved Retacrit (epoetin alfa-epbx) as a biosimilar to Epogen/Procrit (epoetin alfa) for the treatment of anemia caused by chronic kidney disease, chemotherapy, or use of zidovudine in patients with HIV infection. Retacrit is also approved for use before and after surgery to reduce the chance that red blood cell transfusions will be needed because of blood loss during surgery. (Source: World Pharma News)
Source: World Pharma News - May 15, 2018 Category: Pharmaceuticals Tags: Featured FDA Regulatory Affairs Source Type: news

First clues to the causes of multiple sclerosis
Multiple sclerosis, which affects 1 in 1,000 people, is frequently characterised by relapses associated with variable functional impairments including among others vision problems, impairment of locomotor functions or difficulties with speech. There is still no cure for multiple sclerosis, with current treatments largely based on managing symptoms, especially accelerating recovery phases following a relapse and reducing the number and severity of relapses. (Source: World Pharma News)
Source: World Pharma News - May 15, 2018 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Sanofi and Ablynx announce the successful results of the initial tender offer period
Sanofi (Euronext: SAN; NYSE: SNY) and Ablynx (Euronext Brussels and Nasdaq: ABLX) today announced the results of the initial tender offer period of Sanofi's previously announced tender offers to acquire all of the outstanding shares (including shares represented by American Depositary Shares ("ADSs")), warrants and convertible bonds (together, the "Securities") of Ablynx. (Source: World Pharma News)
Source: World Pharma News - May 14, 2018 Category: Pharmaceuticals Tags: Featured Sanofi Business and Industry Source Type: news

Tumor-like spheres help scientists discover smarter cancer drugs
Cancer is a disease often driven by mutations in genes. As researchers learn more about these genes, and the proteins they code for, they are seeking smarter drugs to target them. The ultimate goal is to find ways to stop cancer cells from multiplying out of control, thereby blocking the growth and spread of tumors. (Source: World Pharma News)
Source: World Pharma News - May 14, 2018 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

AstraZeneca provides update on GALATHEA Phase III trial for Fasenra in chronic obstructive pulmonary disease
AstraZeneca and MedImmune, its global biologics research and development arm, today announced top-line results from the GALATHEA Phase III trial for Fasenra (benralizumab) in patients with moderate to very severe chronic obstructive pulmonary disease (COPD). The trial did not meet the primary endpoint of a statistically-significant reduction of exacerbations in patients with COPD. (Source: World Pharma News)
Source: World Pharma News - May 11, 2018 Category: Pharmaceuticals Tags: Featured AstraZeneca Business and Industry Source Type: news

FDA expands approval of Gilenya to treat multiple sclerosis in pediatric patients
The U.S. Food and Drug Administration today approved Gilenya (fingolimod) to treat relapsing multiple sclerosis (MS) in children and adolescents age 10 years and older. This is the first FDA approval of a drug to treat MS in pediatric patients. (Source: World Pharma News)
Source: World Pharma News - May 11, 2018 Category: Pharmaceuticals Tags: Featured FDA Regulatory Affairs Source Type: news

Research suggests a 15-minute 'daily mile' could enhance health of the world's children
Policymakers should consider introducing The Daily Mile to improve the health and fitness of schoolchildren around the world, according to new research led by the Universities of Stirling and Edinburgh. The first study of the popular Daily Mile initiative - which involves children taking a 15-minute break from class to do physical activity - has confirmed it improves fitness, body composition and activity levels in participants. (Source: World Pharma News)
Source: World Pharma News - May 10, 2018 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Alcon Cares Project 100 commits to reducing cataract blindness globally
Alcon, the global leader in eye care and a division of Novartis, has announced Alcon Cares Project 100, which aims to reduce cataract blindness by providing equipment to perform phaco surgeries. Alcon Cares, a foundation that oversees equipment and product donations to those in need, will give 100 reprocessed Infiniti units to eligible clinics in Asia, Central and South America, and Africa over the next three years, making it one of the largest eye care equipment donations of its kind. (Source: World Pharma News)
Source: World Pharma News - May 10, 2018 Category: Pharmaceuticals Tags: Featured Novartis Business and Industry Source Type: news

Applied science may yield more translational research publications than basic science
While translational research can happen at any stage of the research process, a recent investigation of behavioral and social science research awards granted by the NIH between 2008 and 2014 revealed that applied science yielded a higher volume of translational research publications than basic science, according to a study published May in the open-access journal PLOS ONE (Source: World Pharma News)
Source: World Pharma News - May 9, 2018 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

New cancer immunotherapy drugs rapidly reach patients after approval
The majority of patients eligible for cancer immunotherapy drugs known as checkpoint inhibitors received treatment within a few months of FDA approval, according to a new Yale-led study. The finding suggests that cancer immunotherapies are adopted at a much quicker pace than is typical for newly approved medical treatments, the researchers said. (Source: World Pharma News)
Source: World Pharma News - May 9, 2018 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

FDA grants priority review to Roche's cancer immunotherapy TECENTRIQ (atezolizumab) for initial treatment of people with a specific type of metastatic lung cancer
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the US Food and Drug Administration (FDA) has accepted the company's supplemental Biologics License Application (sBLA) and granted Priority Review for TECENTRIQ® (atezolizumab), in combination with Avastin® (bevacizumab), paclitaxel and carboplatin (chemotherapy), for the initial (first-line) treatment of people with metastatic non-squamous non-small cell lung cancer (NSCLC). (Source: World Pharma News)
Source: World Pharma News - May 8, 2018 Category: Pharmaceuticals Tags: Featured Roche Business and Industry Source Type: news

Hypertensive patients may benefit from folic acid supplements
Hypertensive adults with low platelet count who took a combined daily pill of both enalapril and folic acid saw a 73 percent reduction in their risk of first stroke compared to patients who took only enalapril daily, according to a study published in the Journal of the American College of Cardiology. (Source: World Pharma News)
Source: World Pharma News - May 8, 2018 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Chemical octopus catches sneaky cancer clues, trace glycoproteins
Cancer drops sparse chemical hints of its presence early on, but unfortunately, many of them are in a class of biochemicals that could not be detected thoroughly, until now. Researchers at the Georgia Institute of Technology have engineered a chemical trap that exhaustively catches what are called glycoproteins, including minuscule traces that have previously escaped detection. (Source: World Pharma News)
Source: World Pharma News - May 7, 2018 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

AstraZeneca and Luye Pharma Group enter agreement for rights to Seroquel and Seroquel XR in the UK, China and other international markets
AstraZeneca has entered into an agreement with Luye Pharma Group, Ltd. (Luye Pharma) for the sale and licence of the rights to Seroquel and Seroquel XR in the UK, China and other international markets, including Brazil, Australia, Saudi Arabia, Mexico, South Korea, Thailand, Argentina, Malaysia and South Africa. (Source: World Pharma News)
Source: World Pharma News - May 7, 2018 Category: Pharmaceuticals Tags: Featured AstraZeneca Business and Industry Source Type: news

To treat pain, you need to treat the patient
People in chronic pain are some of the most difficult patients to treat. They have complex circumstances that medicine can't always remedy. Pain can be amplified, by depression and anxiety, genetics and quality of life. Genetics can also play a role in how people experience pain. Physicians are less prone to prescribe opioid medication to patients with long-term pain - but they need more treatment options. (Source: World Pharma News)
Source: World Pharma News - May 4, 2018 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Daily aspirin linked to higher risk in men
Men who take once-daily aspirin have nearly double the risk of melanoma compared to men who are not exposed to daily aspirin, reports a new Northwestern Medicine study. Women, however, do not have an increased risk in this large patient population. The study was published April 27 in the Journal of the American Academy of Dermatology. (Source: World Pharma News)
Source: World Pharma News - May 3, 2018 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

New leads on treating dementia and Alzheimer's
A new research study by scientists in Australia and the US provides an explanation for why clinical trials of drugs reducing proteins in the brain that were thought to cause dementia and Alzheimer's have failed. The study has opened the way for potential new treatments with existing drugs. Published online in the journal Human Molecular Genetics, the researchers assembled evidence from a wide range of human studies and animal models of dementia-related diseases to show that inflammation is a major cause, not just a consequence. (Source: World Pharma News)
Source: World Pharma News - May 3, 2018 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

SMi presents the 9th Conference on Biosimilars & Biobetters
26 - 27 September 2018, London, UK. The SMi Group are thrilled to present the 9th annual conference on Biosimilars & Biobetters, taking place on 26th & 27th September in Central London, UK. Following the success of the previous events in both London and the US, Biosimilars and Biobetters UK 2018 will deliver a stellar speaker line-up and bring together a global audience of biosimilar experts to discuss the latest developments and future of the rapidly evolving and expanding biosimilars market. (Source: World Pharma News)
Source: World Pharma News - May 2, 2018 Category: Pharmaceuticals Tags: Featured Events Source Type: news

Novo Nordisk participates in new research project Hypo-RESOLVE to investigate hypoglycaemia and its impact in diabetes
Within the newly started European research project Hypo-RESOLVE, 23 leading international players from academia, industry and civil society have joined forces to find better solutions to alleviate the burden and consequences of hypoglycaemia in diabetes. Diabetes is a global epidemic, currently affecting around 60 million people in Europe. Hypoglycaemia is a common and serious complication of diabetes, particularly affecting people with diabetes on insulin therapy; very low levels of blood glucose can lead to cognitive decline, cardiovascular events and even death. (Source: World Pharma News)
Source: World Pharma News - May 2, 2018 Category: Pharmaceuticals Tags: Featured Novo Nordisk Business and Industry Source Type: news

Analysis links US government global health R & D funding to jobs, economic benefits across states
The Trump Administration's proposal to slash funding to fight global health threats like malaria, Ebola, and HIV/AIDS could cost states thousands of jobs and millions of dollars in economic investment and put the health of residents at risk, according to a new state-by-state analysis released today on Capitol Hill by the Global Health Technologies Coalition (GHTC). This first-of-its-kind analysis quantifies how federal funding to create vaccines and treatments to combat deadly global diseases also benefits American states. (Source: World Pharma News)
Source: World Pharma News - May 1, 2018 Category: Pharmaceuticals Tags: Featured Development Research and Development Source Type: news

Kymriah ® (tisagenlecleucel), first-in-class CAR-T therapy from Novartis, receives second FDA approval to treat appropriate r/r patients with large B-cell lymphoma
Novartis today announced the US Food and Drug Administration (FDA) has approved Kymriah® (tisagenlecleucel) suspension for intravenous infusion for its second indication - the treatment of adult patients with relapsed or refractory (r/r) large B-cell lymphoma after two or more lines of systemic therapy including diffuse large B-cell lymphoma (DLBCL), high grade B-cell lymphoma and DLBCL arising from follicular lymphoma. (Source: World Pharma News)
Source: World Pharma News - May 1, 2018 Category: Pharmaceuticals Tags: Featured Novartis Business and Industry Source Type: news

Not enough women included in some heart disease clinical trials
Women are underrepresented in clinical trials for heart failure, coronary artery disease and acute coronary syndrome but proportionately or overrepresented in trials for hypertension, atrial fibrillation and pulmonary arterial hypertension, when compared to incidence or prevalence of women within each disease population, according to a study in the Journal of the American College of Cardiology. (Source: World Pharma News)
Source: World Pharma News - April 30, 2018 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Roche reports a strong start in 2018
Roche (SIX: RO, ROG; OTCQX: RHHBY) has announced that in the first three months of 2018, Group sales rose 6% to CHF 13.6 billion. Sales in the Pharmaceuticals Division increased 7% to CHF 10.7 billion. A key growth driver was Ocrevus, used to treat two forms of multiple sclerosis. It continued its strong growth in the US and was launched in Europe and additional countries worldwide during the first quarter. (Source: World Pharma News)
Source: World Pharma News - April 30, 2018 Category: Pharmaceuticals Tags: Featured Roche Business and Industry Source Type: news

A potential new weapon in the addiction battle: FDA-approved diabetes and obesity drugs
Cocaine and other drugs of abuse hijack the natural reward circuits in the brain. In part, that's why it's so hard to quit using these substances. Moreover, relapse rates hover between 40 and 60 percent, similar to rates for other chronic conditions like hypertension and Type 1 diabetes. University of Pennsylvania behavioral pharmacologist and neuroscientist Heath Schmidt studies how long-term exposure to drugs such as cocaine, nicotine, and prescription opioids affects the brain and how these changes promote relapse in someone who has kicked the habit. (Source: World Pharma News)
Source: World Pharma News - April 27, 2018 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

SMi presents the 13th Conference on ADMET
9 - 10 July 2018, London, UK. Developments in ADMET and novel technologies determine the properties of a drug candidate in the preclinical stage of drug discovery. Poor ADMET properties are the principal cause for a candidate to fail at any stage of drug development. ADME-Toxicology and Pharmacokinetic studies are the key strategic check-points for pharmaceutical companies to reduce drug discovery cost, and minimise production times. (Source: World Pharma News)
Source: World Pharma News - April 26, 2018 Category: Pharmaceuticals Tags: Featured Events Source Type: news

Boehringer Ingelheim R & D pushes to transcend disease boundaries
Family-owned pharmaceutical company Boehringer Ingelheim has presented its latest pipeline updates at a Research & Development press conference entitled 'Transcending Disease Boundaries', at its global headquarters in Ingelheim, Germany. The company's R&D strategy and current pipeline has the potential to deliver 15 new medicines for approval by 2025 (probability adjusted). (Source: World Pharma News)
Source: World Pharma News - April 26, 2018 Category: Pharmaceuticals Tags: Featured Boehringer Ingelheim Business and Industry Source Type: news

Rabies trick could help treat Parkinson's disease
The rabies virus wreaks havoc on the brain, triggering psychosis and death. To get where it needs to go, the virus must first trick the nervous system and cross the blood brain barrier - a process that makes it of interest in drug design. Now, scientists report in ACS Nano a way to exploit the rabies virus machinery to deliver a Parkinson's disease medication directly to the brain. (Source: World Pharma News)
Source: World Pharma News - April 25, 2018 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Novartis launches FocalView app, providing opportunity for patients to participate in ophthalmology clinical trials from home
Novartis announced the launch of its FocalView app, an ophthalmic digital research platform created with ResearchKit. FocalView aims to allow researchers to track disease progression by collecting real-time, self-reported data directly from consenting patients. By adapting the design of clinical trials to suit the daily routine of patients, the app may reduce barriers to participation, leading to a more nuanced understanding of ophthalmic diseases and potentially accelerating the development of novel treatments. (Source: World Pharma News)
Source: World Pharma News - April 25, 2018 Category: Pharmaceuticals Tags: Featured Novartis Business and Industry Source Type: news

Artificial leaf as mini-factory for medicine
Using sunlight for sustainable and cheap production of, for example, medicines. The 'mini-factory' in the form of a leaf that chemical engineers from Eindhoven University of Technology presented in 2016 showed that it is possible. Now the researchers have come with an improved version: their 'mini-factory' is now able to keep production at the same level, irrespective of the variation in sunlight due to cloudiness or time of the day. (Source: World Pharma News)
Source: World Pharma News - April 24, 2018 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

New OCREVUS (ocrelizumab) data at AAN demonstrate significant reductions in disease activity and disability progression in relapsing multiple sclerosis
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that new OCREVUS (ocrelizumab) data were presented at the 70th American Academy of Neurology (AAN) Annual Meeting from 21-27 April in Los Angeles, California. The data showcase the efficacy of OCREVUS in relapsing multiple sclerosis (RMS) through several measures of underlying disease activity and disability progression, including magnetic resonance imaging (MRI), cognitive function, and spinal fluid biomarkers of inflammation and neurodegeneration. (Source: World Pharma News)
Source: World Pharma News - April 24, 2018 Category: Pharmaceuticals Tags: Featured Roche Business and Industry Source Type: news

Spider venom to treat paralysis
A team of Russian scientists together with foreign colleagues found out that the venom of crab spider Heriaeus melloteei may be used as a basis for developing treatment against hypokalemic periodic paralysis. This disease is caused by genetic mutation that leads to the occurrence of the so-called ω-currents or leakage currents via voltage-gated ion channels Nav1.4 in skeletal muscles. (Source: World Pharma News)
Source: World Pharma News - April 23, 2018 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Pfizer doses first patient using investigational mini-dystrophin gene therapy for the treatment of Duchenne muscular dystrophy
Pfizer Inc. has initiated a Phase 1b clinical trial for its mini-dystrophin gene therapy candidate, PF-06939926, in boys with Duchenne muscular dystrophy (DMD). The first boy received an infusion of the mini-dystrophin gene on March 22nd, administered under the supervision of principal investigator, Edward Smith, MD, Associate Professor of Pediatrics and Neurology at Duke University Medical Center. (Source: World Pharma News)
Source: World Pharma News - April 23, 2018 Category: Pharmaceuticals Tags: Featured Pfizer Business and Industry Source Type: news

Novel antioxidant makes old blood vessels seem young again
Older adults who take a novel antioxidant that specifically targets cellular powerhouses, or mitochondria, see age-related vascular changes reverse by the equivalent of 15 to 20 years within six weeks, according to new University of Colorado Boulder research. The study, published this week in the American Heart Association journal Hypertension, adds to a growing body of evidence suggesting pharmaceutical-grade nutritional supplements, or nutraceuticals, could play an important role in preventing heart disease-the nation's No. 1 killer. (Source: World Pharma News)
Source: World Pharma News - April 20, 2018 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Red Cross and Novo Nordisk announce ground-breaking partnership to tackle chronic care in humanitarian crises
The International Committee of the Red Cross (ICRC), the Danish Red Cross (DRC) and Novo Nordisk today announced a partnership to tackle the growing issue of chronic diseases that affect millions of people living in humanitarian crises around the world. (Source: World Pharma News)
Source: World Pharma News - April 19, 2018 Category: Pharmaceuticals Tags: Featured Novo Nordisk Business and Industry Source Type: news

FDA approves first therapy for rare inherited form of rickets, x-linked hypophosphatemia
The U.S. Food and Drug Administration has approved Crysvita (burosumab-twza), the first drug approved to treat adults and children ages 1 year and older with x-linked hypophosphatemia (XLH), a rare, inherited form of rickets. XLH causes low levels of phosphorus in the blood. It leads to impaired bone growth and development in children and adolescents and problems with bone mineralization throughout a patient's life. (Source: World Pharma News)
Source: World Pharma News - April 19, 2018 Category: Pharmaceuticals Tags: Featured FDA Regulatory Affairs Source Type: news

Music intensifies effects of anti-hypertensive medication
In addition to remembering to take the medication prescribed by their cardiologists at the right times and going to the trouble of making healthy lifestyle changes, patients with high blood pressure (hypertension) can include a pleasing beneficial activity in routine treatment of the disease thanks to the discovery that listening to music significantly enhances the effect of anti-hypertensive drugs. (Source: World Pharma News)
Source: World Pharma News - April 18, 2018 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Diabetes drug may not reduce risk of death
One class of drug used to treat type 2 diabetes may not reduce the risk of death when compared with placebo, suggests new findings. The research, led by scientists from Imperial College London and published in the Journal of the American Medical Association, studied three types of diabetes treatment: sodium-glucose cotransporter 2 (SGLT-2) inhibitors, glucagon-like peptide 1 (GLP-1) agonists, and dipeptidyl peptidase 4 (DPP-4) inhibitors. (Source: World Pharma News)
Source: World Pharma News - April 18, 2018 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

FDA grants Breakthrough Therapy Designation for Roche's Hemlibra in haemophilia A without inhibitors
Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to Hemlibra® (emicizumab-kxwh) for people with haemophilia A without factor VIII inhibitors. Breakthrough Therapy Designation is designed to accelerate the development and review of medicines intended to treat a serious condition with preliminary evidence that indicates they may demonstrate a substantial improvement over existing therapies. (Source: World Pharma News)
Source: World Pharma News - April 17, 2018 Category: Pharmaceuticals Tags: Featured Roche Business and Industry Source Type: news

Novartis renews commitment to malaria elimination, investing USD 100 million to research and develop next-generation antimalarials
Novartis announces a five-year commitment to the fight against malaria in conjunction with the 7th Multilateral Initiative on Malaria Conference and the Malaria Summit of the Commonwealth Heads of Government meeting. Further, the company releases new African research on progress and remaining challenges toward the 2030 malaria elimination targets, together with Elimination 8 and the KEMRI-Wellcome Trust program. (Source: World Pharma News)
Source: World Pharma News - April 17, 2018 Category: Pharmaceuticals Tags: Featured Novartis Business and Industry Source Type: news

Boehringer Ingelheim and Lilly announce an academic collaboration with University of Oxford
Boehringer Ingelheim and Eli Lilly and Company (NYSE:LLY) have announced an academic collaboration with the University of Oxford. EMPA-KIDNEY will investigate the effects of empagliflozin on the progression of kidney disease and the occurrence of cardiovascular death, in people with established chronic kidney disease with and without diabetes. (Source: World Pharma News)
Source: World Pharma News - April 16, 2018 Category: Pharmaceuticals Tags: Featured Boehringer Ingelheim Business and Industry Source Type: news

Bristol-Myers Squibb announces worldwide collaboration with Janssen to develop and commercialize next-generation cardiovascular therapy
Bristol-Myers Squibb Company (NYSE: BMY) today announced a worldwide collaboration with Janssen Pharmaceuticals, Inc. (Janssen) on a Factor XIa (FXIa) inhibitor program that includes the development and commercialization of Bristol-Myers Squibb's Factor XIa (FXIa) inhibitor, BMS-986177, an investigational anticoagulant compound being studied for prevention and treatment of major thrombotic conditions. (Source: World Pharma News)
Source: World Pharma News - April 16, 2018 Category: Pharmaceuticals Tags: Featured Bristol-Myers Squibb Business and Industry Source Type: news

GSK signs strategic agreement to transfer rare disease gene therapy portfolio to Orchard Therapeutics
GSK and Orchard Therapeutics have announced a strategic agreement, under which GSK will transfer its portfolio of approved and investigational rare disease gene therapies to Orchard, securing the continued development of the programmes and access for patients. This acquisition strengthens Orchard's position as a global leader in gene therapy for rare diseases. (Source: World Pharma News)
Source: World Pharma News - April 13, 2018 Category: Pharmaceuticals Tags: Featured GlaxoSmithKline Business and Industry Source Type: news

Bristol-Myers Squibb and Harvard announce new fibrosis research collaboration
Bristol-Myers Squibb Company and the Harvard Fibrosis Network of the Harvard Stem Cell Institute today announce a research collaboration to discover and develop potential new therapies for fibrotic diseases, including fibrosis of the liver and heart. The Harvard Fibrosis Network brings together researchers across the schools and affiliated hospitals of Harvard University. (Source: World Pharma News)
Source: World Pharma News - April 12, 2018 Category: Pharmaceuticals Tags: Featured Bristol-Myers Squibb Business and Industry Source Type: news

Personalized tumor vaccine shows promise in pilot trial
A new type of cancer vaccine has yielded promising results in an initial clinical trial conducted at the Perelman School of Medicine at the University of Pennsylvania and the Abramson Cancer Center of the University of Pennsylvania. The personalized vaccine is made from patients' own immune cells, which are exposed in the laboratory to the contents of the patients' tumor cells, and then injected into the patients to initiate a wider immune response. (Source: World Pharma News)
Source: World Pharma News - April 12, 2018 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

SMi presents the 2nd annual conference on Pharmaceutical Microbiology West Coast
7 - 8 June 2018, San Diego, USA. SMi proudly presents the 2nd Annual Pharmaceutical Microbiology West Coast Conference, in San Diego, USA. The pharmaceutical microbiology field is an ever changing in almost all areas of pharmaceuticals. Therefore, professionals within the field need to be informed and updated on the revised regulations and newly emerging methods and practices. (Source: World Pharma News)
Source: World Pharma News - April 11, 2018 Category: Pharmaceuticals Tags: Featured Events Source Type: news